CTIS2023-506937-30-00进行中（未招募）1 期
UECHUP-MON/23-4
aboratorios Alter S.A.0 个研究点目标入组 36 人开始时间: 2023年7月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Randomised, crossover bioequivalence clinical trial of donepezil 5 mg capsules vs donepezil 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditionsAlzheimer's diseaseCTIS2023-506938-68-00aboratorios Alter S.A.30
进行中（未招募）
1 期
Randomised, crossover bioequivalence clinical trial of apixaban 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditionsCTIS2023-503557-35-00Alter Farmacia S.A.24
进行中（未招募）
1 期
Randomised, crossover bioequivalence clinical trial of linagliptin/metformin 2.5 mg/1000 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fed conditions.diabetesCTIS2024-512310-18-00aboratorios Alter S.A.36
进行中（未招募）
1 期
RANDOMISED, CROSSOVER BIOEQUIVALENCE CLINICAL TRIAL OF APIXABAN 5 MG CAPSULES VS APIXABAN 5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS UNDER FASTING CONDITIONS.thrombosisCTIS2023-506035-15-00aboratorios Alter S.A.36
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.CTIS2024-512770-10-00Sun Pharmaceutical Industries Limited50